ArticleArthritis research & therapy2018

One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.

Leslie R Harrold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.